The Effect of Ipilimumab on the Endocrine Function
| dc.contributor.advisor | McBride, Ali | en |
| dc.contributor.author | Qyra, Ollga | |
| dc.contributor.author | McBride, Ali | |
| dc.date.accessioned | 2016-06-21T20:30:41Z | |
| dc.date.available | 2016-06-21T20:30:41Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | http://hdl.handle.net/10150/613945 | |
| dc.description | Class of 2016 Abstract | en |
| dc.description.abstract | Objectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least one dose of ipilimumab. Results: The primary finding of this study is that 38% of patients used at least 20 mg of prednisone daily or more while on Ipilimumab therapy. Only 33% of patients had endocrine lab values reported. Conclusions: There was not enough data collected to adequately show that Ipilimumab affects the endocrine system. There was also insufficient reporting of appropriate serum levels. More research on the importance of reporting lab values while on ipilimumab therapy needs to be conducted. | |
| dc.language.iso | en_US | en |
| dc.publisher | The University of Arizona. | en |
| dc.rights | Copyright © is held by the author. | en |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | |
| dc.subject | Ipilimumab | en |
| dc.subject | Endocrine | en |
| dc.subject | Metastatic Melanoma | en |
| dc.subject.mesh | Antibodies, Monoclonal | |
| dc.subject.mesh | Endocrine System | |
| dc.subject.mesh | Melanoma | |
| dc.title | The Effect of Ipilimumab on the Endocrine Function | en_US |
| dc.type | text | en |
| dc.type | Electronic Report | en |
| dc.contributor.department | College of Pharmacy, The University of Arizona | en |
| dc.description.collectioninformation | This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu. | en |
| html.description.abstract | Objectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least one dose of ipilimumab. Results: The primary finding of this study is that 38% of patients used at least 20 mg of prednisone daily or more while on Ipilimumab therapy. Only 33% of patients had endocrine lab values reported. Conclusions: There was not enough data collected to adequately show that Ipilimumab affects the endocrine system. There was also insufficient reporting of appropriate serum levels. More research on the importance of reporting lab values while on ipilimumab therapy needs to be conducted. |